Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.98)
# 558
Out of 5,154 analysts
218
Total ratings
58.14%
Success rate
8.35%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $143.93 | +7.69% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $990.33 | +21.68% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $27.05 | -0.18% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $115.79 | +3.64% | 12 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $350 | $369.53 | -5.29% | 19 | Feb 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $740 → $800 | $759.86 | +5.28% | 22 | Feb 2, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $99.41 | +12.66% | 2 | Oct 31, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $230.11 | +8.64% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $456.69 | +6.20% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $60.29 | -8.77% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $59.29 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $128.13 | +28.78% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $27.24 | -26.58% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $184.87 | -2.63% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $15.12 | +296.83% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.60 | +397.51% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.53 | +488.24% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $60.41 | +57.26% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $4.58 | +336.68% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $114.33 | -36.15% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.00 | +500.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.50 | +199.58% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $138.01 | +175.34% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $95.94 | -14.53% | 5 | Jan 16, 2019 |
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $143.93
Upside: +7.69%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $990.33
Upside: +21.68%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $27.05
Upside: -0.18%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $115.79
Upside: +3.64%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $350
Current: $369.53
Upside: -5.29%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $740 → $800
Current: $759.86
Upside: +5.28%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $99.41
Upside: +12.66%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $230.11
Upside: +8.64%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $456.69
Upside: +6.20%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $60.29
Upside: -8.77%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $59.29
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $128.13
Upside: +28.78%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $27.24
Upside: -26.58%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $184.87
Upside: -2.63%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $15.12
Upside: +296.83%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.60
Upside: +397.51%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.53
Upside: +488.24%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $60.41
Upside: +57.26%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $4.58
Upside: +336.68%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $114.33
Upside: -36.15%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.00
Upside: +500.00%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.50
Upside: +199.58%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $138.01
Upside: +175.34%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $95.94
Upside: -14.53%